Polyrizon reports results from study of Trap & Target platform

Polyrizon (PLRZ) Ltd. announced encouraging preclinical results from a recent study evaluating its proprietary hydrogel-based Trap & Target platform. The study, conducted in collaboration with the University of Parma, demonstrated that Polyrizon’s hydrogel formulation achieves targeted deposition in the upper regions of the nasal cavity-critical for central nervous system drug delivery. The promising results are part of a collaborative study between the Company and the Department of Food and Drug of the University of Parma, led and conducted by Professor Fabio Sonvico, a leading expert in the development of intranasal and pulmonary drug delivery solutions and a member of the Company’s Scientific Advisory Board.